Skip to main content

Advertisement

Log in

miR-153 sensitized the K562 cells to As2O3-induced apoptosis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Relapse remains the biggest hurdle of leukemia therapy, while elucidating the molecular mechanism holds promise for the solution. Recently, microRNAs are emerging as an important regulator of cell function. In this study, we for the first time found that miR-153 was downregulated in As2O3-induced drug-resistant K562 cells. In the CD34+ K562 subpopulation, which is characteristic of leukemia stem cell and resembles the drug-resistant subgroup, miR-153 expression level was also much lower than that in the bulk. Forced expression of miR-153 only in K562 cells has no significant effects on cell growth and apoptosis. However, when cells were additionally treated with As2O3, significant greater apoptosis was observed in the miR-153 overexpressed group. Our data here suggest that strategies increasing the endogenous miR-153 might hold promise for an alternative adjuvant therapy of leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3.

    Article  PubMed  CAS  Google Scholar 

  2. Holyoake DT. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol. 2001;113:11–23.

    Article  PubMed  CAS  Google Scholar 

  3. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010–22.

    Article  PubMed  CAS  Google Scholar 

  4. Goldman JM, Melo JV. Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451–64.

    Article  PubMed  CAS  Google Scholar 

  5. Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, Zhang J, Chen GQ, Chen SJ, Chen Z. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104:4219–25.

    Article  PubMed  CAS  Google Scholar 

  6. Gu J, Zhu X, Li Y, Dong D, Yao J, Lin C, Huang K, Hu H, Fei J. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol. Feb 9 [Epub ahead of print].

  7. Gao SM, Chen C, Wu J, Tan Y, Yu K, Xing CY, Ye A, Yin L, Jiang L. Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide. Biochem Biophys Res Commun. 2010;403:203–8.

    Google Scholar 

  8. Zhang QY, Mao JH, Liu P, Huang QH, Lu J, Xie YY, Weng L, Zhang Y, Chen Q, Chen SJ, Chen Z. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009;106:3378–83.

    Article  PubMed  CAS  Google Scholar 

  9. Holtz MS, Forman SJ, Bhatia R. Non proliferating CML CD34 + progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia. 2005;19:1034–41.

    Article  PubMed  CAS  Google Scholar 

  10. Bartel DP. Micro RNAs: genomics. biogenes mech funct Cell. 2004;116:281–97.

    CAS  Google Scholar 

  11. Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev. 2006;16:4–9.

    Article  PubMed  CAS  Google Scholar 

  12. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.

    Article  PubMed  CAS  Google Scholar 

  13. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104:15805–10.

    Article  PubMed  CAS  Google Scholar 

  14. Xu J, Liao X, Wong C. Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer. 2009;126:1029–35.

    Google Scholar 

  15. Liu L, Chen R, Huang S, Wu Y, Li G, Liu Q, Yin D, Liang Y. Knockdown of SOD1 sensitizes the CD34 + CML cells to imatinib therapy. Med Oncol. 2010 Apr 21 [Epub ahead of print].

  16. Chen Y, Peng C, Sullivan C, Li D, Li S. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia. 2010;24:1545–54.

    Article  PubMed  CAS  Google Scholar 

  17. Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci. 2010;101:1577–81.

    Article  PubMed  CAS  Google Scholar 

  18. Hochhaus A, Schenk T, Erben P, Ernst T, La Rosee P, Muller MC. Cause and management of therapy resistance. Best Pract Res Clin Haematol. 2009;22:367–79.

    Article  PubMed  Google Scholar 

  19. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006;43:1–67.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Li Liu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, L., Chen, R., Huang, S. et al. miR-153 sensitized the K562 cells to As2O3-induced apoptosis. Med Oncol 29, 243–247 (2012). https://doi.org/10.1007/s12032-010-9807-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9807-6

Keywords

Navigation